Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy

[1]  A. Sommet,et al.  Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. , 2022, Brain : a journal of neurology.

[2]  R. D. Du Pasquier,et al.  Advances in Treatment of Progressive Multifocal Leukoencephalopathy , 2021, Annals of neurology.

[3]  Bryan R. Smith,et al.  BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study , 2021, The Lancet Neurology.

[4]  D. Reich,et al.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease , 2020, Nature Reviews Neurology.

[5]  Bryan R. Smith,et al.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.

[6]  E. A. Mills,et al.  Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View , 2018, Front. Immunol..

[7]  L. Deangelis,et al.  Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. , 2017, Blood advances.

[8]  J. Honnorat,et al.  Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine , 2016, Clinical Drug Investigation.

[9]  M. Macal,et al.  Innate and Adaptive Immune Regulation During Chronic Viral Infections. , 2015, Annual review of virology.

[10]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[11]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[12]  E. Wherry,et al.  T cell exhaustion during persistent viral infections. , 2015, Virology.

[13]  C. Terborg,et al.  PML in a patient with lymphocytopenia treated with dimethyl fumarate. , 2015, The New England journal of medicine.

[14]  E. Navas,et al.  Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[15]  D. Clifford,et al.  A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes , 2013, Journal of NeuroVirology.

[16]  J. Kilby,et al.  Faculty of 1000 evaluation for Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012 .

[17]  F. Sánchez‐Madrid,et al.  Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis , 2012, PloS one.

[18]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[19]  E. Wherry.  T cell exhaustion , 2011, Nature Immunology.

[20]  I. Koralnik,et al.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.

[21]  L. Calabrese,et al.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. , 2009, Arthritis and rheumatism.

[22]  D. Clifford,et al.  Determinants of survival in progressive multifocal leukoencephalopathy , 2009, Neurology.

[23]  R. Maserati,et al.  JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy , 2009, Journal of NeuroVirology.

[24]  M. Battegay,et al.  Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Berger,et al.  Opportunistic infections and other risks with newer multiple sclerosis therapies , 2009, Annals of neurology.

[26]  C. Marra,et al.  Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis , 2008, AIDS.

[27]  D. Podzamczer,et al.  Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study , 2008, Journal of acquired immune deficiency syndromes.

[28]  S. Shelburne,et al.  Immune reconstitution inflammatory syndrome: more answers, more questions. , 2006, The Journal of antimicrobial chemotherapy.

[29]  L. Teyton,et al.  Intrinsic Functional Dysregulation of CD4 T Cells Occurs Rapidly following Persistent Viral Infection , 2005, Journal of Virology.

[30]  A. Mocroft,et al.  Changing incidence of central nervous system diseases in the EuroSIDA cohort , 2004, Annals of neurology.

[31]  N. Letvin,et al.  JC Virus-Specific Cytotoxic T Lymphocytes in Individuals with Progressive Multifocal Leukoencephalopathy , 2001, Journal of Virology.

[32]  E. Major,et al.  AIDS- and non–AIDS-related PML association with distinct p53 polymorphism , 2000, Neurology.

[33]  R. Zinkernagel,et al.  Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. , 1998, Immunity.

[34]  H. Stellbrink,et al.  Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV‐associated progressive multifocal leukoencephalopathy , 1998, AIDS.

[35]  U. Dafni,et al.  Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. , 1998, The New England journal of medicine.

[36]  D. Granick.  The More Answers, The More Questions , 1962, Slavic Review: Interdisciplinary Quarterly of Russian, Eurasian, and East European Studies.

[37]  Jennifer F Hoy,et al.  Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[38]  A. Lazzarin,et al.  The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature , 2011, Journal of NeuroVirology.

[39]  J. McArthur,et al.  The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS , 2011, Journal of NeuroVirology.

[40]  Anthony J. Manzo,et al.  A bird's eye view tracking slow nanometer-scale movements of single molecular nano-assemblies. , 2010, Methods in enzymology.

[41]  G. Kronborg,et al.  Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. , 2009, The Journal of infectious diseases.

[42]  J. Swieten.  Interobserver Agreement for the Assessment of Handicap in Stroke Patients , 2005 .

[43]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.